CD4+CD25+Tregs的数量或比例，同乳腺癌的病理、转移、预后等密切相关，但乳腺癌原发、转移部位与外周血之间Tregs的区别和联系并没有被阐明。课题组在国内率先建立高通量测序（HTS）CDR3组库的技术和分析平台，前期研究发现乳腺癌患者肿瘤组织、转移淋巴结、外周血之间总T细胞CDR3谱系和CDR3组库存在不同的特征。本申请项目以转MMTV基因FVB小鼠(或鼠乳腺癌细胞系接种小鼠）、自发乳腺肿瘤C3H/He小鼠、临床乳腺癌志愿患者为研究对象，制备肿瘤原发、转移部位组织和外周血样本，分选出CD4+CD25+Tregs和CD4+ CD25– 总T细胞，HTS技术测序出TCR β CDR3组库, 系统对比乳腺癌不同组织部位CD4+CD25+Tregs的异质性，解析乳腺肿瘤微坏境对Tregs的影响，为乳腺癌个体化免疫机制、治疗和预后，提供基于CD4+CD25+Tregs CDR3靶标的新的思路、技术和手段。

CD4+CD25+regulatory T cells (Tregs) is closely related to the type of pathology, metastasis and prognosis of breast cancer. But the relation and difference of Tregs in the primary tumor tissue, the tumor metastatic tissue and peripheral blood has not been elucidated. Our research group established the high-throughput sequencing (HTS) CDR3 repertoire techniques and analysis platform, and discovered the different characteristics of total T cells CDR3 spectratyping and repertoire in the breast cancer tumor tissue, metastatic axillary lymph node and peripheral blood. In this program, we would study the TCR beta chain CDR3 repertoire of CD4+CD25+ Tregs and CD4+ CD25 – total T cells, in the FVB mice with MMTV gene（or breast cancer cell lines inoculated mice）, the spontaneous breast tumor C3H/He mice, the clinical breast cancer volunteers. Analysis of the Tregs TCR beta CDR3 repertoire heterogeneity and homogeneity in the primary tumor tissue, the tumor metastatic tissue, the tumor metastatic axillary lymph node and peripheral blood in the breast cancer of mice and volunteers. To enudleate the influence of Tregs by breast tumor micro environments. And would be provided the CD4+CD25+ Tregs CDR3 target for the individualized immune mechanisms, treatment and prognosis of breast cancer.